Quick Answer
ORTHOPEDIATRICS CORP reported Total Revenue of $236.35 million for fiscal year 2025.
ORTHOPEDIATRICS CORP — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $236.35M +15.4% |
$204.73M +37.6% |
$148.73M +21.6% |
$122.29M +24.7% |
$98.05M +37.9% |
$71.08M -2.0% |
| Revenue (ASC 606) | $236.35M +15.4% |
$204.73M +37.6% |
$148.73M +21.6% |
$122.29M +24.7% |
$98.05M +37.9% |
$71.08M -2.0% |
| Net Income | -$39.65M -4.8% |
-$37.82M -80.3% |
-$20.97M -1767.2% |
$1.26M +107.7% |
-$16.26M +50.6% |
-$32.94M -139.9% |
| Diluted EPS | -$1.69 -3.0% |
-$1.64 -78.3% |
-$0.92 -1633.3% |
$0.06 +107.1% |
-$0.84 +53.8% |
-$1.82 -93.6% |
| Total Assets | $508.63M +7.5% |
$473.21M +7.9% |
$438.75M +2.6% |
$427.73M +40.6% |
$304.27M -5.0% |
$320.41M +75.9% |
| Cash and Equivalents | $19.56M -55.4% |
$43.82M +41.1% |
$31.05M +245.4% |
$8.99M +17.7% |
$7.64M -73.4% |
$28.76M -59.4% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $346.60M -2.2% |
$354.57M -6.0% |
$377.02M -0.4% |
$378.65M +68.0% |
$225.37M -4.0% |
$234.77M +64.9% |
| R&D Expense | $9.10M -17.5% |
$11.03M +1.3% |
$10.89M +28.9% |
$8.45M +52.5% |
$5.54M +5.1% |
$5.27M -8.3% |
| Operating Income | -$39.24M -12.1% |
-$35.01M -30.9% |
-$26.75M -5.3% |
-$25.40M -40.9% |
-$18.02M +32.6% |
-$26.75M -194.8% |
| Gross Profit | $172.66M +16.2% |
$148.60M +33.6% |
$111.25M +22.7% |
$90.66M +23.5% |
$73.40M +33.4% |
$55.03M +0.8% |
| Shares Outstanding | 25.09M +3.6% |
24.22M +3.6% |
23.38M +2.2% |
22.88M +16.3% |
19.68M +0.6% |
19.56M +17.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $61.25M | +12.2% | +0.3% |
| Revenue (ASC 606) | September 30, 2025 | $61.25M | +12.2% | +0.3% |
| Net Income | September 30, 2025 | -$11.77M | -48.7% | -65.5% |
| Diluted EPS | September 30, 2025 | -$0.50 | -47.1% | -66.7% |
| Total Assets | September 30, 2025 | $493.49M | +0.9% | -2.0% |
| Cash and Equivalents | September 30, 2025 | $16.83M | -67.0% | -62.2% |
| Long-Term Debt | March 31, 2019 | $21.13M | -16.5% | -0.1% |
| Stockholders Equity | September 30, 2025 | $349.31M | -5.8% | -1.7% |
| R&D Expense | September 30, 2025 | $2.33M | -9.5% | +8.1% |
| Operating Income | September 30, 2025 | -$9.43M | -69.4% | +11.5% |
| Gross Profit | September 30, 2025 | $45.27M | +13.0% | +2.9% |
| Shares Outstanding | September 30, 2023 | 23.35M | +2.0% | +0.0% |
- ORTHOPEDIATRICS CORP reported Total Revenue of $236.35 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed an increase of +15.4% in Total Revenue compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Revenue (ASC 606) of $236.35 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed an increase of +15.4% in Revenue (ASC 606) compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Net Income of -$39.65 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed a decrease of -4.8% in Net Income compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Diluted EPS of $1.69 per share (loss) for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed a decrease of -3.0% in Diluted EPS compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Total Assets of $508.63 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed an increase of +7.5% in Total Assets compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Cash and Equivalents of $19.56 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed a decrease of -55.4% in Cash and Equivalents compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Long-Term Debt of $21.16 million for fiscal year 2018.
- ORTHOPEDIATRICS CORP showed a decrease of -16.5% in Long-Term Debt compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Stockholders Equity of $346.60 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed a decrease of -2.2% in Stockholders Equity compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported R&D Expense of $9.10 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed a decrease of -17.5% in R&D Expense compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Operating Income of -$39.24 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed a decrease of -12.1% in Operating Income compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Gross Profit of $172.66 million for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed an increase of +16.2% in Gross Profit compared to the prior fiscal year.
- ORTHOPEDIATRICS CORP reported Shares Outstanding of 25.09 million shares for fiscal year 2025.
- ORTHOPEDIATRICS CORP showed an increase of +3.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: